Bioinformatics for cancer immunotherapy target discovery

Lars Rønn Olsen, Benito Campos, Mike Stein Barnkob, Ole Winther, Vladimir Brusic, Mads Hald Andersen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.

Original languageEnglish
Pages (from-to)1235-1249
Number of pages15
JournalCancer Immunology, Immunotherapy
Volume63
Issue number12
DOIs
Publication statusPublished - Dec 4 2014

Fingerprint

Computational Biology
Immunotherapy
Epitopes
Neoplasms
Cataloging
Neoplasm Antigens
Therapeutics
Immune System
Databases
Proteins

Keywords

  • Biological databases
  • Cancer vaccines
  • Computational biology
  • T cell epitopes
  • Tumor antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Olsen, L. R., Campos, B., Barnkob, M. S., Winther, O., Brusic, V., & Andersen, M. H. (2014). Bioinformatics for cancer immunotherapy target discovery. Cancer Immunology, Immunotherapy, 63(12), 1235-1249. https://doi.org/10.1007/s00262-014-1627-7

Bioinformatics for cancer immunotherapy target discovery. / Olsen, Lars Rønn; Campos, Benito; Barnkob, Mike Stein; Winther, Ole; Brusic, Vladimir; Andersen, Mads Hald.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 12, 04.12.2014, p. 1235-1249.

Research output: Contribution to journalArticle

Olsen, LR, Campos, B, Barnkob, MS, Winther, O, Brusic, V & Andersen, MH 2014, 'Bioinformatics for cancer immunotherapy target discovery', Cancer Immunology, Immunotherapy, vol. 63, no. 12, pp. 1235-1249. https://doi.org/10.1007/s00262-014-1627-7
Olsen LR, Campos B, Barnkob MS, Winther O, Brusic V, Andersen MH. Bioinformatics for cancer immunotherapy target discovery. Cancer Immunology, Immunotherapy. 2014 Dec 4;63(12):1235-1249. https://doi.org/10.1007/s00262-014-1627-7
Olsen, Lars Rønn ; Campos, Benito ; Barnkob, Mike Stein ; Winther, Ole ; Brusic, Vladimir ; Andersen, Mads Hald. / Bioinformatics for cancer immunotherapy target discovery. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 12. pp. 1235-1249.
@article{c81377c33fb0495297c8cbf67b935b6d,
title = "Bioinformatics for cancer immunotherapy target discovery",
abstract = "The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.",
keywords = "Biological databases, Cancer vaccines, Computational biology, T cell epitopes, Tumor antigens",
author = "Olsen, {Lars R{\o}nn} and Benito Campos and Barnkob, {Mike Stein} and Ole Winther and Vladimir Brusic and Andersen, {Mads Hald}",
year = "2014",
month = "12",
day = "4",
doi = "10.1007/s00262-014-1627-7",
language = "English",
volume = "63",
pages = "1235--1249",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",

}

TY - JOUR

T1 - Bioinformatics for cancer immunotherapy target discovery

AU - Olsen, Lars Rønn

AU - Campos, Benito

AU - Barnkob, Mike Stein

AU - Winther, Ole

AU - Brusic, Vladimir

AU - Andersen, Mads Hald

PY - 2014/12/4

Y1 - 2014/12/4

N2 - The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.

AB - The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.

KW - Biological databases

KW - Cancer vaccines

KW - Computational biology

KW - T cell epitopes

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=84916598431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916598431&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1627-7

DO - 10.1007/s00262-014-1627-7

M3 - Article

C2 - 25344903

AN - SCOPUS:84916598431

VL - 63

SP - 1235

EP - 1249

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 12

ER -